Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 72,831,288
  • Shares Outstanding, K 211,430
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.77
  • Price/Sales 6.20
  • Price/Cash Flow 14.20
  • Price/Book 6.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
303.00 +13.69%
on 09/29/17
348.65 -1.20%
on 10/17/17
+23.21 (+7.22%)
since 09/15/17
3-Month
280.01 +23.02%
on 07/24/17
348.65 -1.20%
on 10/17/17
+61.82 (+21.87%)
since 07/17/17
52-Week
244.28 +41.01%
on 05/31/17
348.65 -1.20%
on 10/17/17
+75.81 (+28.22%)
since 10/17/16

Most Recent Stories

More News
Where to Find Value in Healthcare Stocks

The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

AET : 155.90 (+2.95%)
ABBV : 92.17 (+1.24%)
GILD : 80.24 (+0.36%)
TEVA : 14.74 (+0.20%)
BIIB : 344.47 (+2.62%)
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

CELG : 138.86 (+1.57%)
VRTX : 155.05 (+0.23%)
CLVS : 81.32 (-3.85%)
ABBV : 92.17 (+1.24%)
REGN : 442.56 (-0.70%)
AMGN : 186.19 (+2.36%)
BIIB : 344.47 (+2.62%)
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.

MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
VRTX : 155.05 (+0.23%)
NVS : 86.34 (-0.03%)
GILD : 80.24 (+0.36%)
PFE : 36.20 (+0.61%)
BIIB : 344.47 (+2.62%)
Align Biopharma Introduces New Technology Standard to Enable Single Sign-on for Healthcare Providers

Align Biopharma(TM), a life sciences industry technology standards group, today published a final open technology standard for identity management. Members from leading pharmaceutical,...

VEEV : 59.58 (+1.59%)
BIIB : 344.47 (+2.62%)
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

EBS : 40.08 (-1.21%)
ACAD : 36.99 (+2.47%)
SNY : 49.59 (-0.08%)
BIIB : 344.47 (+2.62%)
Constellation Brands and Biogen rise; Navient plunges

NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday:

NAVI : 12.20 (+4.01%)
STZ : 213.64 (+1.52%)
UPS : 117.68 (-0.56%)
FDX : 220.10 (-0.56%)
BKE : 15.65 (+1.62%)
BIIB : 344.47 (+2.62%)
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status

ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.

ACAD : 36.99 (+2.47%)
ADAP : 7.01 (-4.37%)
ADRO : 9.65 (+1.58%)
BIIB : 344.47 (+2.62%)
Catabasis' DMD Candidate Slows Disease Progression, Stock Up

Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

PTCT : 18.13 (+1.23%)
CATB : 2.29 (-2.97%)
SRPT : 51.72 (+1.95%)
BIIB : 344.47 (+2.62%)
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience

Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.

LGND : 142.15 (+0.29%)
ACAD : 36.99 (+2.47%)
ADRO : 9.65 (+1.58%)
BIIB : 344.47 (+2.62%)
Biogen's SPINRAZA(R) (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy

--Phase 2 EMBRACE interim analysis showed greater motor milestone achievement in infants and children treated with SPINRAZA, compared to those untreated, in patient populations not studied in the pivotal...

IONS : 63.85 (+4.42%)
BIIB : 344.47 (+2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 353.23
1st Resistance Point 348.85
Last Price 344.47
1st Support Level 339.89
2nd Support Level 335.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart